Bionano Genomics has appointed Kristiina Vuori to its board of directors. Vuori is president and a board member of the Sanford Burnham Prebys Medical Discovery Institute (SBP.) She also serves as a professor at SBP's National Cancer Institute-designated Cancer Center. She holds an MD and PhD from Finland's University of Oulu. Her research has helped delineate molecular pathways that regulate cancer cell survival, motility, metastasis, and drug responsiveness. Her molecular characterization of prolyl hydroxylase helped to enable the formation of FibroGen.